Medical Services & Publications

SHERIDAN, WYOMING – November 07, 2024 – In an effort to combat the largest blood shortage in a generation, Abbott and the Big Ten Conference have joined forces to launch "The We Give Blood Drive," a conference-wide competition aimed at increasing blood donations. This initiative taps into the competitive spirit of Big Ten universities and their fans, encouraging them to give back to their communities while vying for a $1 million prize and a trip to the 2024 Discover Big Ten Football Championship Game. The competition, which kicked off on September 26th, has already seen tremendous support, with over 8,000 Big Ten fans, students, and alumni donating blood.

SHERIDAN, WYOMING – November 07, 2024 – Abbott (NYSE: ABT) today announced significant strides in its pulsed field ablation (PFA) solutions within the electrophysiology field. The company has achieved key milestones, including the early completion of enrollment in the VOLT-AF IDE Study for the Volt™ PFA System and the initiation of the FOCALFLEX trial to evaluate the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), designed for treating paroxysmal atrial fibrillation. These advancements underscore Abbott's commitment to providing innovative solutions for abnormal heart rhythms like atrial fibrillation (AFib).

SHERIDAN, WYOMING – November 07, 2024 – GE HealthCare, a leading global medical technology and diagnostics company, is poised to announce its latest quarterly earnings before the market opens on Wednesday. Financial analysts are predicting an increase in both revenue and profits compared to the same period last year, signaling continued resilience amidst a challenging global economic landscape.

SHERIDAN, WYOMING – November 07, 2024-Roche (SIX: RO, ROG; OTCQX: RHHBY) has opened its new Pharma Research and Early Development Center (pRED) at its global headquarters in Basel. The center has 1,800 laboratory and office workplaces, bringing together researchers from different disciplines, explains Roche in a statement. The center’s inauguration was attended by Federal Councillor Guy Parmelin, Head of the Federal Department of Economic Affairs, Education and Research.

SHERIDAN, WYOMING – November 07, 2024 – Roche, a global pioneer in pharmaceuticals and diagnostics, is set to present a robust body of data at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. With more than 40 abstracts spanning nine blood disorders, Roche's presence at ASH underscores its unwavering dedication to improving outcomes for individuals battling lymphoma.

SHERIDAN, WYOMING – November 7, 2024 – Roche, a global healthcare pioneer, has announced continued strong sales growth in the third quarter of 2024. The company's performance was driven by high demand for both its Pharmaceuticals and Diagnostics divisions, with Group sales increasing by 9% at constant exchange rates (CER). [cite: 1, 2, 3] “Our strong growth momentum continued in the third quarter, reflecting the high demand for our innovative medicines and diagnostic solutions and their positive impact on patients’ lives around the world,” said Roche CEO Thomas Schinecker. Pharmaceuticals Division

SHERIDAN, WYOMING – November 06, 2024– Elevate your Pilates practice with the Infinity Reformer, a revolutionary apparatus crafted with unparalleled quality and designed for ultimate versatility. As the only reformer on the market constructed from Lyptus® FAS – the highest quality wood with reforestation certification – the Infinity Reformer provides a stable and elegant foundation for precise and effective Pilates workouts. Whether you're a seasoned Pilates enthusiast, a patient in physical therapy, or a high-performance athlete, the Infinity Reformer adapts to your needs and goals. With the ability to perform over 200 exercises, this exceptional piece of equipment empowers you to strengthen your core, improve flexibility, and enhance overall well-being.

SHERIDAN, WYOMING – November 06, 2024 – In a groundbreaking move towards personalized cancer care, GE HealthCare announced yesterday its collaboration with University Medicine Essen (UME) to establish a cutting-edge Theranostics Center of Excellence. This partnership aims to transform cancer treatment by leveraging advanced technologies, innovative tracers, and artificial intelligence to provide patients with tailored therapies and improved outcomes

SHERIDAN, WYOMING – November 06, 2024 – GE HealthCare, a pioneer in digital nuclear medicine and a frontrunner in artificial intelligence (AI), has once again raised the bar for innovation with the introduction of Aurora, a groundbreaking SPECT/CT system. Aurora is designed to empower clinicians with enhanced capabilities, potentially expanding the range of procedures available to patients

SHERIDAN, WYOMING – NOVEMBER 05, 2024 – In a landmark phase III study published in the New England Journal of Medicine, Roche's Itovebi (inavolisib) has demonstrated a significant breakthrough in the treatment of HR-positive advanced breast cancer. The Itovebi-based regimen more than doubled progression-free survival compared to the standard treatment of palbociclib and fulvestrant alone. The INAVO120 study evaluated Itovebi in combination with palbociclib and fulvestrant in patients with HR-positive, HER2-negative breast cancer with a PIK3CA mutation, one of the most common mutations in this type of cancer. The results were striking, with the Itovebi-based regimen reducing the risk of disease progression or death by 57%. [cite: 1, 2, 7]